<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31923223</article-id><article-id pub-id-type="pmc">6953806</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0227365</article-id><article-id pub-id-type="publisher-id">PONE-D-19-17178</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Heart Failure</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Coronary Heart Disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Coronary Heart Disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aromatic Amino Acids</subject><subj-group><subject>Tryptophan</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aromatic Amino Acids</subject><subj-group><subject>Tryptophan</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aromatic Amino Acids</subject><subj-group><subject>Tryptophan</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Myocardial Infarction</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Metabolism</subject><subj-group><subject>Metabolites</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiovascular Medicine</subject><subj-group><subject>Cardiovascular Imaging</subject><subj-group><subject>Angiography</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Cardiovascular Imaging</subject><subj-group><subject>Angiography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Imaging Techniques</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Cardiovascular Imaging</subject><subj-group><subject>Angiography</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Radiology and Imaging</subject><subj-group><subject>Diagnostic Radiology</subject><subj-group><subject>Cardiovascular Imaging</subject><subj-group><subject>Angiography</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Plasma kynurenines and prognosis in patients with heart failure</article-title><alt-title alt-title-type="running-head">Kynurenines and heart failure</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9183-4814</contrib-id><name><surname>Lund</surname><given-names>Anders</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Nordrehaug</surname><given-names>Jan Erik</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Slettom</surname><given-names>Grete</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hafstad Solvang</surname><given-names>Stein-Erik</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ringdal Pedersen</surname><given-names>Eva Kristine</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2937-5351</contrib-id><name><surname>Midttun</surname><given-names>&#x000d8;ivind</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ulvik</surname><given-names>Arve</given-names></name><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ueland</surname><given-names>Per Magne</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nyg&#x000e5;rd</surname><given-names>Ottar</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Melvaer Giil</surname><given-names>Lasse</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Clinical Science, University of Bergen, Bergen, Norway</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Cardiology, Stavanger University Hospital, Stavanger, Norway</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Heart Disease, Haukeland University Hospital, Bergen, Norway</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Bevital AS, Bergen, Norway</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Guillemin</surname><given-names>Gilles J.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Macquarie University, AUSTRALIA</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>One or more of the authors are employed by a commercial company, Bevital AS. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><corresp id="cor001">* E-mail: <email>lund.anders88@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>15</volume><issue>1</issue><elocation-id>e0227365</elocation-id><history><date date-type="received"><day>17</day><month>6</month><year>2019</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Lund et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Lund et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0227365.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Metabolites of the kynurenine pathway (mKP) relate to important aspects of heart failure pathophysiology, such as inflammation, energy-homeostasis, apoptosis, and oxidative stress. We aimed to investigate whether mKP predict mortality in patients with heart failure.</p></sec><sec id="sec002"><title>Methods</title><p>The study included 202 patients with heart failure (73.8% with coronary artery disease (CAD)), propensity score matched to 384 controls without heart disease, and 807 controls with CAD (71%). All underwent coronary angiography and ventriculography at baseline. Plasma mKP, pyridoxal 5&#x02019;phosphate (PLP) and CRP were measured at baseline. Case-control differences were assessed by logistic regression and survival by Cox regression, adjusted for age, gender, smoking, diabetes, ejection fraction, PLP, eGFR and CRP. Effect measures are reported per standard deviation increments.</p></sec><sec id="sec003"><title>Results</title><p>Higher plasma levels of kynurenine, 3- hydroxykynurenine (HK), quinolinic acid (QA), the kynurenine-tryptophan-ratio (KTR) and the ratio of HK to xanthurenic acid (HK/XA) were detected in heart failure compared to both control groups. The mortality rate per 1000 person-years was 55.5 in patients with heart failure, 14.6 in controls without heart disease and 22.2 in CAD controls. QA [HR 1.80, p = 0.013], HK [HR 1.77, p = 0.005], HK/XA [HR 1.67, p &#x0003c; 0.001] and KTR [HR 1.55, p = 0.009] were associated with increased mortality in patients with heart failure, while XA [HR 0.68&#x02013;0.80, p = 0.013&#x02013;0.037] were associated with lower mortality in all groups. HK and HK/XA had weak associations with increased mortality in CAD-controls.</p></sec><sec id="sec004"><title>Conclusion</title><p>Elevated plasma levels of mKP and metabolite ratios are associated with increased mortality, independent of CAD, in patients with heart failure.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100005029</institution-id><institution>Helse Vest Regionalt Helsef&#x000f8;retak</institution></institution-wrap></funding-source><award-id>912072</award-id><principal-award-recipient><name><surname>Nordrehaug</surname><given-names>Jan Erik</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by the Western Norway Regional Health Authority [grant number 912072]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. One or more of the authors are employed by a commercial company, Bevital AS. Bevital AS is owned by a non-profit organization and did not play a role in this study.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data cannot be shared publicly because of sharing of de-identified data without patients&#x02019; consent is not approved by an ethics committee. Due to a big data-set and many variables which can possibly identify patients, public sharing of de-identified data cannot be done. This also includes minimal data set as described by PLOS ONE. This case has been discussed with the Data Protection Officer of Haukeland University Hospital. The Data Protection Officer can help with access to data upon request. For data access request, Jonas Magnussen, engineer at the Department of Heart Disease, Haukeland University Hospital, can be contacted at: <email>jonas.magnussen@helse-bergen.no</email>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data cannot be shared publicly because of sharing of de-identified data without patients&#x02019; consent is not approved by an ethics committee. Due to a big data-set and many variables which can possibly identify patients, public sharing of de-identified data cannot be done. This also includes minimal data set as described by PLOS ONE. This case has been discussed with the Data Protection Officer of Haukeland University Hospital. The Data Protection Officer can help with access to data upon request. For data access request, Jonas Magnussen, engineer at the Department of Heart Disease, Haukeland University Hospital, can be contacted at: <email>jonas.magnussen@helse-bergen.no</email>.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Heart failure is associated with chronic inflammation, oxidative stress and cell-death, reflected by an increase in relevant biomarkers [<xref rid="pone.0227365.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0227365.ref003" ref-type="bibr">3</xref>]. Recruitment and activation of monocytes in the myocardium is considered a key pathophysiological process. Activated monocytes and macrophages, stimulate myocardial fibrosis [<xref rid="pone.0227365.ref004" ref-type="bibr">4</xref>] and generate metabolites of the kynurenine pathway (mKP) from the essential amino acid tryptophan. mKP may mediate immunomodulation, oxidant defence and apoptosis [<xref rid="pone.0227365.ref005" ref-type="bibr">5</xref>], which are considered pathogenic features in the development of heart failure.</p><p><xref ref-type="fig" rid="pone.0227365.g001">Fig 1</xref> illustrates the kynurenine pathway (KP). Glucocorticoids and cytokines induce the rate-limiting enzymes tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) who converts tryptophan (Trp) to kynurenine (Kyn) [<xref rid="pone.0227365.ref006" ref-type="bibr">6</xref>]. Interferon gamma (IFN-&#x003b3;) activates the enzymes IDO and KMO [<xref rid="pone.0227365.ref005" ref-type="bibr">5</xref>]. Consequently, an increase in IFN-&#x003b3; activity in patients with heart failure [<xref rid="pone.0227365.ref007" ref-type="bibr">7</xref>], may potentially result in elevated circulating levels of mKP.</p><fig id="pone.0227365.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227365.g001</object-id><label>Fig 1</label><caption><title>The kynurenine pathway.</title><p>The kynurenine pathway (KP) is the major route of Trp degradation. The first step is the formation of formylkynurenine from Trp, catalysed by hepatic tryptophan 2,3-dioxygenase (TDO), predominantly expressed in the liver, or indoleamine-2,3-dioxygenase (IDO), expressed in monocytes. Formylkynurenine is rapidly converted to kynurenine (Kyn). Kyn in turn is converted to a variety of metabolites, many of which have immunomodulatory effects. These include 3-hydroxykynurenine (HK, formed by the flavin adenine dinucleotide (FAD)-dependent kynurenine monooxygenase (KMO)), kynurenic acid (KA) and xanthurenic acid (XA) (products of the pyridoxal 5-phosphate (PLP)-dependent kynurenine aminotransferase (KAT)), anthranilic acid (AA) and 3-hydroxyanthranilic acid (HAA) (products of the pyridoxal 5-phosphate (PLP)-dependent kynureninase (KYNU). HAA is further fully oxidized and in the process produce picolinic acid (not shown in figure) or converted to quinolinic acid (QA) in several steps and further to nicotinic acid mononucleotide and ultimately to NAD+. Abbreviations: KP, kynurenine pathway; AA, anthranilic acid; FAD, flavin adenine dinucleotide; HAA, 3-hydroxyanthranilic acid; HAAO, 3-hydroxyanthranilate 3,4-dioxygenase; HK, 3-hydroxykynurenine; IDO, indoleamine (2,3)-dioxygenase; KA, kynurenic acid; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; Kyn, kynurenine; KYNU, kynureninase; PLP, pyridoxal 5&#x000b4;-phosphate; TDO, tryptophan (2,3)-dioxygenase; Trp, tryptophan; QA, quinolinic acid; QPRT, quinolinate phosphoribosyltransferase; XA, xanthurenic acid; NAM, nicotinamide; NAD, nicotinamide adenine dinucleotide.</p></caption><graphic xlink:href="pone.0227365.g001"/></fig><p>Plasma levels of mKP predict prognosis in both healthy populations and in patients with cardiovascular disease. In a community-based cohort [<xref rid="pone.0227365.ref008" ref-type="bibr">8</xref>], mKP levels predicted all-cause mortality and cardiovascular mortality. In patients with stable angina pectoris and coronary artery disease (CAD), mKP predicted incident myocardial infarction [<xref rid="pone.0227365.ref009" ref-type="bibr">9</xref>]. The levels of the metabolite Kyn were increased in heart failure compared to controls [<xref rid="pone.0227365.ref010" ref-type="bibr">10</xref>]. In the same study, Kyn was associated with increased mortality, but other mKP were not measured [<xref rid="pone.0227365.ref010" ref-type="bibr">10</xref>]. CAD is frequent in patients with heart failure, and mKP have been hypothesized as a driver of CAD itself [<xref rid="pone.0227365.ref008" ref-type="bibr">8</xref>].</p><p>In this study, we aimed to investigate if Trp and mKP predict all-cause mortality in patients with established heart failure, compared to 2 control groups without heart failure, but with or without CAD.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>Study participants</title><p>Patients were recruited from the Western Norway Coronary Angiography Cohort (WECAC) between 1999&#x02013;2004. All patients (N = 4164) underwent elective coronary angiography at Haukeland- or Stavanger University Hospital mostly due to chest pain. Heart failure was identified in 202 patients. Two control groups were matched to these patients (as described below).</p><p>Patient characteristics were obtained at baseline. This included a medical history, self-administered questionnaires, a review of hospital records, and a clinical examination. A trained cardiologist performed cardiac catheterization. Significant coronary stenoses were confirmed in orthogonal views. The number of significantly stenosed vessels defined the severity of CAD (0 to 3). A stenosis in the left main stem counted as a two-vessel disease. Left ventricular ejection fraction (EF) was determined by ventriculography.</p><p>Self-report, a fasting glucose &#x02265; 7.0 mmol/L or non-fasting glucose &#x0003e; 11.1 mmol/L defined diabetes. Self-report and a serum cotinine level &#x02265; 85 nmol/L defined smoking status [<xref rid="pone.0227365.ref011" ref-type="bibr">11</xref>]. Blood samples were drawn at baseline. All-cause mortality was registered from The Norwegian Cause of Death Registry, which covers 98% of the Norwegian population [<xref rid="pone.0227365.ref012" ref-type="bibr">12</xref>]. The censoring date in this study, 31.12.2013, was the time of the last link between the study and the registry.</p></sec><sec id="sec008"><title>Case definitions and propensity score matching</title><p>Heart failure was diagnosed in patients with symptoms, or on treatment, with a left ventricular ejection fraction (LVEF) &#x02264;40% or LVEF &#x0003c;50% and New York Heart Association (NYHA) class &#x02265;2, resulting in 202 patients with heart failure. One-hundred and forty-one (69.8%) patients reported a diagnosis of heart failure. Renin-angiotensin inhibitors were used by 155 (76.7%), beta-blockers by 147 (72.8%), loop diuretics by 121 (59.9%) and 187 (92.5%) used either. Exclusion criteria were severe pulmonary disease, known cancer at baseline, dialysis-demanding renal failure and other terminal illness.</p><p>Two control groups were generated by three steps. First, patients from WECAC without criteria for heart failure, self-reported heart failure, and who were not on loop diuretics were considered potential controls. Second, cases with missing data (&#x0003c; 5%) were removed. This left 3425 potential controls. From these potential controls one subgroup was generated without CAD (NCAD-C), based on no significant stenoses on coronary angiography and no previous myocardial infarction. All potential controls were matched to the heart failure group on age, gender, the severity of CAD, and/or previous myocardial infarction using propensity score matching, generating a control group with proportional CAD to the HF group (CAD-C). The subgroup without CAD was matched to the heart failure group on age and gender, again using propensity score matching, generating CAD-free controls (NCAD-C). <xref ref-type="fig" rid="pone.0227365.g002">Fig 2</xref> illustrates a flow-chart of the matching process.</p><fig id="pone.0227365.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227365.g002</object-id><label>Fig 2</label><caption><title>Propensity score matching of cases and controls.</title><p>3425 patients were identified as potential controls, who did not meet criteria for heart failure and did not report having a diagnosis of heart failure and did not use loop diuretics. These potential controls were propensity score matched to the heart failure group based on age, gender, number of vessels affected by CAD and prior MI generating controls with similar levels of CAD as the heart failure group (CAD-C). A subgroup of the potential controls without CAD and prior MI were propensity score matched based on age and gender, generating a control group without CAD (NCAD-C). Abbreviations: CAD, coronary artery disease represented by number of vessels affected by significant coronary artery stenosis on coronary angiography; MI, myocardial infarction; WECAC, western norway coronary angiography cohort; CAD-C coronary artery disease controls; NCAD-C, non-coronary artery disease controls.</p></caption><graphic xlink:href="pone.0227365.g002"/></fig><p>Propensity score matching was performed using the nearest neighbor algorithm, with random matching order and caliper set to 0.2, as recommended [<xref rid="pone.0227365.ref013" ref-type="bibr">13</xref>]. Cardiovascular risk factors and renal function were not matched for, as this would generate selection bias. Due to the limited number of matching variables, the groups were treated as independent in subsequent statistical analyses.</p></sec><sec id="sec009"><title>Ethics</title><p>This study was approved by the Regional Ethics Committee (REC) West, University of Bergen, Faculty of Medicine, Bergen, Norway, with identification number 2013/2022. All patients provided written consent after the study procedures had been explained in detail.</p></sec><sec id="sec010"><title>Measurements of metabolites and biomarkers</title><p>Blood samples were collected in tubes containing ethylenediamine tetraacetic acid (EDTA) from non-fasting participants. Trp, Kyn, 3-hydroxykynurenine (HK), kynurenic acid (KA), anthranilic acid (AA), 3-hydroxyanthranilic acid (HAA), xanthurenic acid (XA), quinolinic acid (QA), and PLP were measured by Bevital AS (<ext-link ext-link-type="uri" xlink:href="http://www.bevital.no">http://www.bevital.no</ext-link>) using liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay [<xref rid="pone.0227365.ref014" ref-type="bibr">14</xref>]. The Kyn to Trp ratio (KTR) was calculated as Kyn (in nmol/L) divided by Trp (in &#x003bc;mol/L), as was the ratio of HK to XA (HK/XA).</p><p>Serum C-reactive protein (CRP) was measured using an ultrasensitive immunoassay by the Behring nephelometer II system (N Latex CRP mono, Behring Diagnostics, Marburg, Germany). Creatinine was measured by the hospital laboratories. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.</p></sec><sec id="sec011"><title>Missing data</title><p>Fifty-four patients did not have measurements of QA in the heart failure group. These missing data could be predicted from the independent variables (<italic>X</italic><sup>2</sup> 20.3, p = 0.009, Little&#x02019;s test). The missing data for QA were imputed by multiple imputation. The strongest independent predictors of QA, Kyn, and HK were used for imputation together with age, gender, current smoking (estimated from cotinine [<xref rid="pone.0227365.ref011" ref-type="bibr">11</xref>]), eGFR, EF, PLP, CRP, and diabetes. The missing data were imputed 200 times and pooled estimates for all imputations are reported for QA [<xref rid="pone.0227365.ref015" ref-type="bibr">15</xref>].</p></sec><sec id="sec012"><title>Statistics</title><p>T-tests, Mann Whitney U-test, Chi-square, and log-rank tests were used for univariate analysis. Variables with non-normal distributions were transformed prior to multivariate analyses, according to Tukey&#x02019;s ladder of powers (square root, logarithms, 1/square root, and inverse). All variables were subsequently standardized to their respective z-scores, calculated as z = (x&#x02013; &#x003bc;) / &#x003c3;, where x is the variable, &#x003bc; its mean and &#x003c3; its standard deviation. Each resulting data-point is then scaled to reflect the number of standard deviations it lies from a mean of zero. The aim of standardization was to make effect sizes of variables on different scales and transformations more comparable.</p><p>Metabolites were analyzed in separate multivariate models to avoid collinearity. We used logistic regression to estimate the differences between cases and controls, adjusted for potential confounders (CRP, diabetes, eGFR, PLP and Trp). From the significant models in logistic regression, we wanted to evaluate if kynurenines could be used as diagnostic biomarkers of heart failure. We evaluated metabolites and derived ratios separately. Using Lasso with all significant metabolites identified, or ratios, we identified the optimal multivariate logistic regression model using the default cross-validation method to identify &#x003bb;. From this model, the predicted probabilities from the logistic regressions were used as the predictor of the diagnostic categories using receiver operating characteristic (ROC) analysis, which were presented graphically. The area under the curve (AUC) was estimated. We also estimated sensitivity and specificity directly from the logistic regression models using the post-hoc analysis tool &#x0201c;estat class&#x0201d; in Stata 16.</p><p>The hazard for all-cause mortality associated with metabolite levels was estimated using Cox proportional hazard analysis for patients with heart failure and the two control groups (CAD-C and NCAD-C). These analyses were adjusted for age, gender, CRP, diabetes, current smoking, eGFR, PLP, and Trp. The assumption of proportional hazards was checked in stratified analyses for categorical variables. For continuous variables, it was evaluated by inspecting Shoenfeld residuals and by performing the Therneau and Grampsch test.</p><p>The Benjamini-Hochberg procedure was used to adjust for multiple comparisons, at a false discovery rate (FDR) of 0.05 and FDR-adjusted p-values are reported (Q-values). The number of tests were estimated by summarizing all case-control comparisons and the hypotheses of association with mortality for the heart failure group. Statistical analyses and corresponding graphs were conducted with Stata 15 and 16 (Stata Statistical Software: Release 15 and 16. College Station, TX: StataCorp LLC), R version 3.3.2 (packages: PM Match and p.adjust).</p></sec><sec id="sec013"><title>Confounders</title><p>The potential confounders eGFR, Trp, diabetes, PLP and CRP were selected <italic>a priori</italic> and included in the multivariate models [<xref rid="pone.0227365.ref016" ref-type="bibr">16</xref>], as the primary aim was to identify independent associations with mKP and end points. Both renal function and protein intake could be reduced in heart failure [<xref rid="pone.0227365.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0227365.ref018" ref-type="bibr">18</xref>]. Plasma levels of mKP are strongly related to renal function [<xref rid="pone.0227365.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0227365.ref020" ref-type="bibr">20</xref>], and availability of the substrate Trp is linked to protein intake and downstream levels [<xref rid="pone.0227365.ref021" ref-type="bibr">21</xref>]. Trp was not included as a confounder when KTR was evaluated, as KTR is a product of Trp and Kyn. Patients with diabetes have higher levels of mKP and diabetes is an individual predictor for heart failure [<xref rid="pone.0227365.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0227365.ref023" ref-type="bibr">23</xref>]. PLP is an essential co-factor for KAT and KYNU [<xref rid="pone.0227365.ref020" ref-type="bibr">20</xref>], and have been found to be related to plasma levels of several mKP [<xref rid="pone.0227365.ref024" ref-type="bibr">24</xref>]. Elevated CRP is associated with a diagnosis of heart failure and increased mortality in heart failure [<xref rid="pone.0227365.ref025" ref-type="bibr">25</xref>]. CRP is an unspecific marker of systemic inflammation and could thus be indirectly associated with IDO-activation [<xref rid="pone.0227365.ref026" ref-type="bibr">26</xref>], supported by association with plasma levels of several mKP [<xref rid="pone.0227365.ref027" ref-type="bibr">27</xref>].</p></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><sec id="sec015"><title>Characteristics of the study participants</title><p><xref rid="pone.0227365.t001" ref-type="table">Table 1</xref> summarizes group characteristics. Compared with both control groups, patients with heart failure had lower eGFR, higher CRP, and a higher prevalence of diabetes. PLP levels were lower in patients with heart failure compared to the NCAD-C group. The heart failure and both control groups were well matched for age and gender. The CAD-C group was, in addition, well matched on previous MI and number of vessels with coronary artery stenosis. Among the patients with open coronary arteries at baseline, there were higher prevalence of previous myocardial infarction and/or percutaneous coronary intervention in the CAD-C group compared to patients with heart failure.</p><table-wrap id="pone.0227365.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227365.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics and group mortality.</title></caption><alternatives><graphic id="pone.0227365.t001g" xlink:href="pone.0227365.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Clinical Characteristics</th><th align="center" rowspan="2" colspan="1">Heart failure<break/>(N = 202)</th><th align="center" colspan="2" rowspan="1">Controls<break/>(N = 1191)</th></tr><tr><th align="center" rowspan="1" colspan="1">NCAD-C<break/>(N = 384)</th><th align="center" rowspan="1" colspan="1">CAD-C<break/>(N = 807)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x02003;Age, years; mean (SD) <xref ref-type="table-fn" rid="t001fn003"><sup>a</sup></xref></td><td align="center" rowspan="1" colspan="1">63.1 (9.1)</td><td align="center" rowspan="1" colspan="1">61.5 (9.1)</td><td align="center" rowspan="1" colspan="1">62.8 (9.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male; N (%) <xref ref-type="table-fn" rid="t001fn004"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">155 (76.7)</td><td align="center" rowspan="1" colspan="1">277 (72.1)</td><td align="center" rowspan="1" colspan="1">606 (75.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Body mass index; mean (SD) <xref ref-type="table-fn" rid="t001fn003"><sup>a</sup></xref></td><td align="center" rowspan="1" colspan="1">26.1 (4.2)</td><td align="center" rowspan="1" colspan="1">26.3 (3.7)</td><td align="center" rowspan="1" colspan="1">26.6 (3.8)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Risk Factors and Possible Confounders</bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diabetes; N (%) <xref ref-type="table-fn" rid="t001fn004"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">32 (16.3)</td><td align="center" rowspan="1" colspan="1">21 (5.5)<xref ref-type="table-fn" rid="t001fn009">*</xref></td><td align="center" rowspan="1" colspan="1">79 (9.8)<xref ref-type="table-fn" rid="t001fn009">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Current smoker; N (%) <xref ref-type="table-fn" rid="t001fn004"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">63 (31.2)</td><td align="center" rowspan="1" colspan="1">101 (26.3)</td><td align="center" rowspan="1" colspan="1">260 (32.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypertension; N (%) <xref ref-type="table-fn" rid="t001fn004"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">97 (48.7)</td><td align="center" rowspan="1" colspan="1">169 (44.0)</td><td align="center" rowspan="1" colspan="1">402 (49.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;eGFR, ml/min/1.73<sup>2</sup>; mean (SD) <xref ref-type="table-fn" rid="t001fn003"><sup>a</sup></xref></td><td align="center" rowspan="1" colspan="1">83 (28)</td><td align="center" rowspan="1" colspan="1">88.9 (14)<xref ref-type="table-fn" rid="t001fn010">**</xref></td><td align="center" rowspan="1" colspan="1">88.4 (15.1)<xref ref-type="table-fn" rid="t001fn010">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CRP, mg/L; median (IQR) <xref ref-type="table-fn" rid="t001fn005"><sup>c</sup></xref></td><td align="center" rowspan="1" colspan="1">2.9 (3.6)</td><td align="center" rowspan="1" colspan="1">1.5 (2.4)<xref ref-type="table-fn" rid="t001fn010">**</xref></td><td align="center" rowspan="1" colspan="1">1.9 (3.2)<xref ref-type="table-fn" rid="t001fn010">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PLP, nmol/L; median (IQR) <xref ref-type="table-fn" rid="t001fn005"><sup>c</sup></xref></td><td align="center" rowspan="1" colspan="1">43.4 (38.7)</td><td align="center" rowspan="1" colspan="1">47.0 (34.4)<xref ref-type="table-fn" rid="t001fn009">*</xref></td><td align="center" rowspan="1" colspan="1">40.8 (31.4)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Cardiac Disease</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Prior myocardial infarction; N (%) <xref ref-type="table-fn" rid="t001fn004"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">135 (66.8)</td><td align="center" rowspan="1" colspan="1">0 (0)<xref ref-type="table-fn" rid="t001fn010">**</xref></td><td align="center" rowspan="1" colspan="1">520 (64.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Coronary artery stenosis; N (%) <xref ref-type="table-fn" rid="t001fn004"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;0</td><td align="center" rowspan="1" colspan="1">53 (26.2)<xref ref-type="table-fn" rid="t001fn007"><sup>#</sup></xref></td><td align="center" rowspan="1" colspan="1">384 (100)<xref ref-type="table-fn" rid="t001fn010">**</xref></td><td align="center" rowspan="1" colspan="1">234 (29)<xref ref-type="table-fn" rid="t001fn008"><sup>$</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;1</td><td align="center" rowspan="1" colspan="1">30 (14.9)</td><td align="center" rowspan="1" colspan="1">0<xref ref-type="table-fn" rid="t001fn010">**</xref></td><td align="center" rowspan="1" colspan="1">119 (14.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;2</td><td align="center" rowspan="1" colspan="1">31 (15.3)</td><td align="center" rowspan="1" colspan="1">0<xref ref-type="table-fn" rid="t001fn010">**</xref></td><td align="center" rowspan="1" colspan="1">108 (13.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;3</td><td align="center" rowspan="1" colspan="1">88 (43.6)</td><td align="center" rowspan="1" colspan="1">0<xref ref-type="table-fn" rid="t001fn010">**</xref></td><td align="center" rowspan="1" colspan="1">346 (42.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ejection fraction; median (IQR) <xref ref-type="table-fn" rid="t001fn005"><sup>c</sup></xref></td><td align="center" rowspan="1" colspan="1">34.0 (8.4)</td><td align="center" rowspan="1" colspan="1">70 (5)<xref ref-type="table-fn" rid="t001fn010">**</xref></td><td align="center" rowspan="1" colspan="1">65 (10)<xref ref-type="table-fn" rid="t001fn010">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>All-Cause Mortality</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Deceased, N (%) <xref ref-type="table-fn" rid="t001fn006"><sup>d</sup></xref></td><td align="center" rowspan="1" colspan="1">94 (46.5)</td><td align="center" rowspan="1" colspan="1">56 (14.6)<xref ref-type="table-fn" rid="t001fn010">**</xref></td><td align="center" rowspan="1" colspan="1">180 (22.3)<xref ref-type="table-fn" rid="t001fn010">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mortality rate, per 1000 PY</td><td align="center" rowspan="1" colspan="1">55.5</td><td align="center" rowspan="1" colspan="1">14.6</td><td align="center" rowspan="1" colspan="1">22.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mean follow up time, years</td><td align="center" rowspan="1" colspan="1">9.6</td><td align="center" rowspan="1" colspan="1">10.0</td><td align="center" rowspan="1" colspan="1">10.0</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Abbreviations: CAD-C, controls with coronary artery disease; CRP, C-reactive protein; N, number of patients; NCAD-C, controls free of coronary artery disease; PY, person-years; PLP, pyridoxal 5&#x02019;phosphate; SD, standard deviation.</p></fn><fn id="t001fn002"><p>Tests comparing heart failure to controls:</p></fn><fn id="t001fn003"><p><sup>a</sup> Students T-test</p></fn><fn id="t001fn004"><p><sup>b</sup> Chi square test</p></fn><fn id="t001fn005"><p><sup>c</sup> Mann-Whitney U test</p></fn><fn id="t001fn006"><p><sup>d</sup> Log-rank test</p></fn><fn id="t001fn007"><p><sup>#</sup> 9 (17%) with previous MI. 3 (6.7%) with previous PCI. 43 (81%) with no previous MI or PCI.</p></fn><fn id="t001fn008"><p><sup>$</sup> 83 (35.5%) with previous MI. 50 (21%) with previous PCI. 139 (59.4%) with no previous MI or PCI.</p></fn><fn id="t001fn009"><p>* p-value &#x0003c; 0.05,</p></fn><fn id="t001fn010"><p>** p-value &#x0003c; 0.001</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec016"><title>Metabolites of the kynurenine pathway in patients with heart failure and control groups</title><p>Unadjusted plasma levels of Kyn, HK, KA, AA, HAA, QA, KTR, and HK/XA were higher in patients with heart failure compared to both control groups (<xref ref-type="supplementary-material" rid="pone.0227365.s001">S1 Table</xref>). Adjusted for confounders and multiple comparisons, patients with heart failure had higher levels of Kyn, HK, QA, KTR, and HK/XA ratio compared to both control groups (<xref rid="pone.0227365.t002" ref-type="table">Table 2</xref>). From the metabolites, we identified a model with Trp and Kyn (and HK in CAD-C group) and both KTR and HK/XA, using Lasso. ROC curves from multivariate logistic regression gave an AUC of 0.7 for Trp and Kyn and an AUC of 0.69 for KTR and HK/XA with HF versus NCAD-C as outcome, and an AUC of 0.69 for Trp, Kyn and HK, and an AUC of 0.65 with HF versus CAD-C as outcome. Further, adding these kynurenines to models with confounders have only minimal improvement in AUC (See <xref ref-type="supplementary-material" rid="pone.0227365.s002">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0227365.s003">S2</xref> Figs in supporting material).</p><table-wrap id="pone.0227365.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227365.t002</object-id><label>Table 2</label><caption><title>Tryptophan and metabolites of the kynurenine pathway in heart failure.</title><p>Adjusted analyses <xref ref-type="table-fn" rid="t002fn002"><sup>a</sup></xref>.</p></caption><alternatives><graphic id="pone.0227365.t002g" xlink:href="pone.0227365.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" colspan="4" rowspan="1">HF versus NCAD-C <xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></th><th align="center" colspan="4" rowspan="1">HF versus CAD-C <xref ref-type="table-fn" rid="t002fn004"><sup>c</sup></xref></th></tr><tr><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">p</th><th align="center" rowspan="1" colspan="1">Q <xref ref-type="table-fn" rid="t002fn005"><sup>d</sup></xref></th><th align="center" rowspan="1" colspan="1">OR</th><th align="center" rowspan="1" colspan="1">95% CI</th><th align="center" rowspan="1" colspan="1">p</th><th align="center" rowspan="1" colspan="1">Q <xref ref-type="table-fn" rid="t002fn005"><sup>d</sup></xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Trp</td><td align="char" char="." rowspan="1" colspan="1">1.08</td><td align="center" rowspan="1" colspan="1">0.89&#x02013;1.31</td><td align="char" char="." rowspan="1" colspan="1">.44</td><td align="char" char="." rowspan="1" colspan="1">.53</td><td align="char" char="." rowspan="1" colspan="1">1.22</td><td align="center" rowspan="1" colspan="1">1.04&#x02013;1.45</td><td align="char" char="." rowspan="1" colspan="1">.017<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.034<xref ref-type="table-fn" rid="t002fn006">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Kyn</td><td align="char" char="." rowspan="1" colspan="1">1.94</td><td align="center" rowspan="1" colspan="1">1.47&#x02013;2.56</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c; .001<xref ref-type="table-fn" rid="t002fn007">**</xref></td><td align="char" char="." rowspan="1" colspan="1">&#x0003c; .001<xref ref-type="table-fn" rid="t002fn007">**</xref></td><td align="char" char="." rowspan="1" colspan="1">1.69</td><td align="center" rowspan="1" colspan="1">1.35&#x02013;2.11</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c; .001<xref ref-type="table-fn" rid="t002fn007">**</xref></td><td align="char" char="." rowspan="1" colspan="1">&#x0003c; .001<xref ref-type="table-fn" rid="t002fn007">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">HK</td><td align="char" char="." rowspan="1" colspan="1">1.50</td><td align="center" rowspan="1" colspan="1">1.13&#x02013;2.00</td><td align="char" char="." rowspan="1" colspan="1">.005<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.014<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">1.46</td><td align="center" rowspan="1" colspan="1">1.16&#x02013;1.85</td><td align="char" char="." rowspan="1" colspan="1">.001<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.005<xref ref-type="table-fn" rid="t002fn006">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">KA</td><td align="char" char="." rowspan="1" colspan="1">1.15</td><td align="center" rowspan="1" colspan="1">0.90&#x02013;1.48</td><td align="char" char="." rowspan="1" colspan="1">.26</td><td align="char" char="." rowspan="1" colspan="1">.36</td><td align="char" char="." rowspan="1" colspan="1">1.11</td><td align="center" rowspan="1" colspan="1">0.90&#x02013;1.37</td><td align="char" char="." rowspan="1" colspan="1">.31</td><td align="char" char="." rowspan="1" colspan="1">.40</td></tr><tr><td align="left" rowspan="1" colspan="1">XA</td><td align="char" char="." rowspan="1" colspan="1">0.90</td><td align="center" rowspan="1" colspan="1">0.72&#x02013;1.14</td><td align="char" char="." rowspan="1" colspan="1">.40</td><td align="char" char="." rowspan="1" colspan="1">.50</td><td align="char" char="." rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0.79&#x02013;1.17</td><td align="char" char="." rowspan="1" colspan="1">.71</td><td align="char" char="." rowspan="1" colspan="1">.71</td></tr><tr><td align="left" rowspan="1" colspan="1">AA</td><td align="char" char="." rowspan="1" colspan="1">1.16</td><td align="center" rowspan="1" colspan="1">0.94&#x02013;1.45</td><td align="char" char="." rowspan="1" colspan="1">.16</td><td align="char" char="." rowspan="1" colspan="1">.25</td><td align="char" char="." rowspan="1" colspan="1">1.05</td><td align="center" rowspan="1" colspan="1">0.87&#x02013;1.26</td><td align="char" char="." rowspan="1" colspan="1">.62</td><td align="char" char="." rowspan="1" colspan="1">.64</td></tr><tr><td align="left" rowspan="1" colspan="1">HAA</td><td align="char" char="." rowspan="1" colspan="1">1.07</td><td align="center" rowspan="1" colspan="1">0.87&#x02013;1.33</td><td align="char" char="." rowspan="1" colspan="1">.52</td><td align="char" char="." rowspan="1" colspan="1">.59</td><td align="char" char="." rowspan="1" colspan="1">0.89</td><td align="center" rowspan="1" colspan="1">0.74&#x02013;1.08</td><td align="char" char="." rowspan="1" colspan="1">.23</td><td align="char" char="." rowspan="1" colspan="1">.35</td></tr><tr><td align="left" rowspan="1" colspan="1">QA</td><td align="char" char="." rowspan="1" colspan="1">1.54</td><td align="center" rowspan="1" colspan="1">1.18&#x02013;2.01</td><td align="char" char="." rowspan="1" colspan="1">.002<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.007<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">1.44</td><td align="center" rowspan="1" colspan="1">1.15&#x02013;1.79</td><td align="char" char="." rowspan="1" colspan="1">.001<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.005<xref ref-type="table-fn" rid="t002fn006">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">KTR</td><td align="char" char="." rowspan="1" colspan="1">1.72</td><td align="center" rowspan="1" colspan="1">1.31&#x02013;2.26</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c; .001<xref ref-type="table-fn" rid="t002fn007">**</xref></td><td align="char" char="." rowspan="1" colspan="1">.001<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">1.41</td><td align="center" rowspan="1" colspan="1">1.14&#x02013;1.74</td><td align="char" char="." rowspan="1" colspan="1">.001<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.005<xref ref-type="table-fn" rid="t002fn006">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">HK/XA</td><td align="char" char="." rowspan="1" colspan="1">1.30</td><td align="center" rowspan="1" colspan="1">1.04&#x02013;1.64</td><td align="char" char="." rowspan="1" colspan="1">.024<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.045<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">1.42</td><td align="center" rowspan="1" colspan="1">1.16&#x02013;1.73</td><td align="char" char="." rowspan="1" colspan="1">.001<xref ref-type="table-fn" rid="t002fn006">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.005<xref ref-type="table-fn" rid="t002fn006">*</xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Case-control differences evaluated by logistic regression. Abbreviations: AA, anthranilic acid; CI, confidence interval; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio; KA, kynurenic acid; KTR, kynurenine-tryptophan ratio; Kyn, kynurenine; OR, odds ratio; SD; standard deviation; QA, quinolinic acid; XA, xanthurenic acid.</p></fn><fn id="t002fn002"><p><sup>a</sup> Odds ratios per 1 SD of the predictor by logistic regression.</p></fn><fn id="t002fn003"><p><sup>b</sup> Heart failure (HF, N = 202) vs controls without coronary artery disease (NCAD-C, N = 384) as outcome, adjusted for diabetes, glomerular filtration rate, pyridoxal 5&#x02019;phosphate, C-reactive protein and Trp (not Trp in KTR model).</p></fn><fn id="t002fn004"><p><sup>c</sup> HF (N = 202) vs controls with coronary artery disease (CAD-C, N = 807). Covariates as in model <sup>b</sup>.</p></fn><fn id="t002fn005"><p><sup>d</sup> p-value adjusted for multiple comparisons in the study (Benjamini-Hochberg; 0.05)</p></fn><fn id="t002fn006"><p>* p-value (p) or q-value (Q) &#x0003c; 0.05,</p></fn><fn id="t002fn007"><p>** p-value or q-value &#x0003c; 0.001</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec017"><title>Metabolites of the kynurenine pathway and all-cause mortality</title><p>Mortality differed significantly between the heart failure (46.5% died), NCAD-C (14.6%) and CAD-C (22.3%) groups. The median follow-up time was similar (9.6 years in heart failure, 10 years in NCAD-C and CAD-C). The mortality rate per 1000 person-years was 55.5 in patients with heart failure, 14.6 in CAD controls and 22.2 in NCAD controls (<xref rid="pone.0227365.t001" ref-type="table">Table 1</xref>).</p><p>In patients with heart failure, HK, QA, KTR and the HK/XA ratio were associated with increased risk of all-cause mortality, whereas XA was associated with a lower risk of all-cause mortality in all three groups. HK and the HK/XA ratio had a weaker association with mortality in the CAD-C group. Kyn, QA, and KTR were not associated with mortality in the control groups (<xref rid="pone.0227365.t003" ref-type="table">Table 3</xref>). <xref ref-type="fig" rid="pone.0227365.g003">Fig 3</xref> illustrate the strongest associations identified in adjusted analyses using Cox regression. Of note, the co-factor PLP was not associated with mortality (HR 0.90&#x02013;1.06, p 0.209&#x02013;0.706) in either group.</p><fig id="pone.0227365.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227365.g003</object-id><label>Fig 3</label><caption><title>3-hydroxykynurenine, xanthurenic acid, quinolinic acid, the kynurenine-to-tryptophan ratio and survival.</title><p>Predicted estimates from Cox regression with age, gender, current smoking, estimated glomerular filtration rate, diabetes mellitus, C-reactive protein and pyridoxal 5&#x02019;phosphate as covariates. The analyses were performed in each group (HF, CAD-C and NCAD-C). The predicted estimates are shown at the mean level of each metabolite (black line), and 1 standard deviation above (red line) and below (blue line) the mean. Abbreviations: HF, heart failure; CAD-C, coronary artery disease controls; NCAD-C, non-coronary artery disease controls; HK, 3-hydroxykynurenic acid; XA, xanthurenic acid; KTR, kynurenine to tryptophan ratio; QA, quinolinic acid; SD, standard deviation.</p></caption><graphic xlink:href="pone.0227365.g003"/></fig><table-wrap id="pone.0227365.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0227365.t003</object-id><label>Table 3</label><caption><title>Tryptophan, kynurenines and mortality in cases and controls <xref ref-type="table-fn" rid="t003fn003"><sup>a</sup></xref>.</title></caption><alternatives><graphic id="pone.0227365.t003g" xlink:href="pone.0227365.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" colspan="3" rowspan="1">Heart Failure</th><th align="center" colspan="2" rowspan="1">NCAD-C</th><th align="center" colspan="2" rowspan="1">CAD-C</th></tr><tr><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1">p</th><th align="center" rowspan="1" colspan="1">Q <xref ref-type="table-fn" rid="t003fn004"><sup>b</sup></xref></th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1">p</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Trp</td><td align="center" rowspan="1" colspan="1">0.83 (0.7&#x02013;1.0)</td><td align="char" char="." rowspan="1" colspan="1">.10</td><td align="char" char="." rowspan="1" colspan="1">.17</td><td align="center" rowspan="1" colspan="1">0.90 (0.7&#x02013;1.2)</td><td align="char" char="." rowspan="1" colspan="1">.45</td><td align="center" rowspan="1" colspan="1">1.07 (0.9&#x02013;1.3)</td><td align="char" char="." rowspan="1" colspan="1">.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Kyn</td><td align="center" rowspan="1" colspan="1">1.41 (1.1&#x02013;1.9)</td><td align="char" char="." rowspan="1" colspan="1">.029<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.051</td><td align="center" rowspan="1" colspan="1">0.99 (0.7&#x02013;1.46)</td><td align="char" char="." rowspan="1" colspan="1">.98</td><td align="center" rowspan="1" colspan="1">0.99 (0.8&#x02013;1.2)</td><td align="char" char="." rowspan="1" colspan="1">.98</td></tr><tr><td align="left" rowspan="1" colspan="1">HK</td><td align="center" rowspan="1" colspan="1">1.77 (1.2&#x02013;2.6)</td><td align="char" char="." rowspan="1" colspan="1">.005<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.014<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="center" rowspan="1" colspan="1">0.91 (0.6&#x02013;1.4)</td><td align="char" char="." rowspan="1" colspan="1">.68</td><td align="center" rowspan="1" colspan="1">1.31 (1.1&#x02013;1.6)</td><td align="char" char="." rowspan="1" colspan="1">.004<xref ref-type="table-fn" rid="t003fn005">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">KA</td><td align="center" rowspan="1" colspan="1">0.90 (0.6&#x02013;1.3)</td><td align="char" char="." rowspan="1" colspan="1">.58</td><td align="char" char="." rowspan="1" colspan="1">.62</td><td align="center" rowspan="1" colspan="1">0.79 (0.6&#x02013;1.1)</td><td align="char" char="." rowspan="1" colspan="1">.21</td><td align="center" rowspan="1" colspan="1">0.87 (0.7&#x02013;1.0)</td><td align="char" char="." rowspan="1" colspan="1">.12</td></tr><tr><td align="left" rowspan="1" colspan="1">XA</td><td align="center" rowspan="1" colspan="1">0.68 (0.7&#x02013;1.2)</td><td align="char" char="." rowspan="1" colspan="1">.011<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.025<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="center" rowspan="1" colspan="1">0.67 (0.5&#x02013;0.9)</td><td align="char" char="." rowspan="1" colspan="1">.029<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="center" rowspan="1" colspan="1">0.83 (0.7&#x02013;0.9)</td><td align="char" char="." rowspan="1" colspan="1">.037<xref ref-type="table-fn" rid="t003fn005">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">AA</td><td align="center" rowspan="1" colspan="1">1.07 (0.8&#x02013;1.4)</td><td align="char" char="." rowspan="1" colspan="1">.58</td><td align="char" char="." rowspan="1" colspan="1">.61</td><td align="center" rowspan="1" colspan="1">1.04 (0.8&#x02013;1.4)</td><td align="char" char="." rowspan="1" colspan="1">.78</td><td align="center" rowspan="1" colspan="1">1.00 (0.9&#x02013;1.2)</td><td align="char" char="." rowspan="1" colspan="1">.99</td></tr><tr><td align="left" rowspan="1" colspan="1">HAA</td><td align="center" rowspan="1" colspan="1">1.14 (0.9&#x02013;1.5)</td><td align="char" char="." rowspan="1" colspan="1">.28</td><td align="char" char="." rowspan="1" colspan="1">.39</td><td align="center" rowspan="1" colspan="1">0.73 (0.5&#x02013;1.0)</td><td align="char" char="." rowspan="1" colspan="1">.070</td><td align="center" rowspan="1" colspan="1">1.13 (1.0&#x02013;1.3)</td><td align="char" char="." rowspan="1" colspan="1">.14</td></tr><tr><td align="left" rowspan="1" colspan="1">QA</td><td align="center" rowspan="1" colspan="1">1.80 (1.1&#x02013;2.9)</td><td align="char" char="." rowspan="1" colspan="1">.013<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.028<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="center" rowspan="1" colspan="1">1.03 (0.8&#x02013;1.4)</td><td align="char" char="." rowspan="1" colspan="1">.86</td><td align="center" rowspan="1" colspan="1">1.18 (1.0&#x02013;1.4)</td><td align="char" char="." rowspan="1" colspan="1">.077</td></tr><tr><td align="left" rowspan="1" colspan="1">KTR</td><td align="center" rowspan="1" colspan="1">1.55 (1.1&#x02013;2.2)</td><td align="char" char="." rowspan="1" colspan="1">.009<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="char" char="." rowspan="1" colspan="1">.023<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="center" rowspan="1" colspan="1">1.01 (0.7&#x02013;1.5)</td><td align="char" char="." rowspan="1" colspan="1">.96</td><td align="center" rowspan="1" colspan="1">0.98 (0.8&#x02013;1.8)</td><td align="char" char="." rowspan="1" colspan="1">.85</td></tr><tr><td align="left" rowspan="1" colspan="1">HK/XA</td><td align="center" rowspan="1" colspan="1">1.67 (1.3&#x02013;2.2)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c; .001<xref ref-type="table-fn" rid="t003fn006">**</xref></td><td align="char" char="." rowspan="1" colspan="1">.003<xref ref-type="table-fn" rid="t003fn005">*</xref></td><td align="center" rowspan="1" colspan="1">1.31 (0.9&#x02013;2.0)</td><td align="char" char="." rowspan="1" colspan="1">.19</td><td align="center" rowspan="1" colspan="1">1.40 (1.2&#x02013;1.7)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c; .001<xref ref-type="table-fn" rid="t003fn006">**</xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>Risk factors for all-cause mortality assessed in patients with heart failure, and in controls with (CAD-C) and without (NCAD-C) coronary heart disease. Each metabolite in separate model.</p></fn><fn id="t003fn002"><p>Abbreviations: AA, anthranilic acid; CI, confidence interval; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio; HR, hazard ratio; KA, kynurenic acid; KTR, kynurenine-tryptophan ratio; Kyn, kynurenine; p, p-value; SD; standard deviation; Trp, tryptophan; Q, q-value, QA, quinolinic acid; XA, xanthurenic acid.</p></fn><fn id="t003fn003"><p><sup>a</sup> Hazard ratio per 1 SD of the predictor by Cox proportional hazard analysis with all-cause mortality as the outcome, adjusted for age, gender, diabetes, current smoking, ejection fraction, estimated glomerular filtration rate, C-reactive protein, pyridoxal 5&#x02019;phosphate and Trp (all metabolites in separate models. KTR not adjusted for Trp).</p></fn><fn id="t003fn004"><p><sup>b</sup> p-value adjusted for multiple comparisons in the study (Benjamini-Hochberg; 0.05)</p></fn><fn id="t003fn005"><p>* p-value or q-value &#x0003c; 0.05,</p></fn><fn id="t003fn006"><p>** p-value &#x0003c; 0.001</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec018"><title>Discussion</title><p>The mKP Kyn, HK, and QA and derived ratios KTR and HK/XA were higher in heart failure patients compared to controls with or without CAD. HK, QA, KTR and the HK/XA ratio were associated with higher all-cause mortality in heart failure. XA was consistently associated with lower mortality in all groups.</p><p>Strengths of this study include a systematic evaluation of CAD and EF with coronary angiography and ventriculography at baseline, an adequate sample size and comprehensive assessment of metabolites. The results were adjusted for relevant confounders and multiple comparisons. Patients in the control groups underwent elective coronary angiography, and thus might not be considered a healthy population. However, they had no history of, or received no treatment for heart failure. All matching procedures are associated with some risk of selection bias which cannot fully be addressed by increasing the number of matching variables, due to the risk of overmatching. Further, mortality in the control groups were considerably lower than in the heart failure group, reducing the statistical power. Finally, we determined biomarkers only at baseline. Despite good-to-fair intra-class correlation coefficients of the included biomarkers (0.67 to 0.44) over a period of 38 months [<xref rid="pone.0227365.ref028" ref-type="bibr">28</xref>], repeated measures would have been informative.</p><p>Kyn levels in our study were higher in heart failure compared to both control groups. This is in line with previous findings [<xref rid="pone.0227365.ref010" ref-type="bibr">10</xref>]. Adding to prior studies, we found higher HK and QA, and the ratios KTR and HK/XA were also elevated in patients with heart failure. Notably, the same findings were observed compared to controls with or without CAD. Despite the association between heart failure and CAD, our findings indicated that heart failure itself is associated with these alterations in mKP, independent of CAD.</p><p>The mKP as predictors of HF did not improve diagnostic prediction in a clinically meaningful way as evaluated by AUC derived from ROC curves, and sensitivity and specificity from logistic regression. This study did not include known predictors (biomarkers) of HF, like N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and we could therefore not compare gold standard biomarkers with mKP, as predictors of HF. LVEF could have possibly been compared as a predictor of HF, but LVEF was included as a case definition parameter, generating spuriously high predictive value. However, as the KP is an essential and tightly regulated physiological pathway, it is unlikely that mKP concentrations will deviate so far from the norm that they can be used to clearly separate populations. As a further consequence of its key physiological role, it is likely to be affected by a range of human diseases. Even if mKP are likely poor diagnostic biomarkers, this does not preclude a role in the pathophysiology of heart failure.</p><p>Blood levels of pro-inflammatory mediators are elevated in heart failure [<xref rid="pone.0227365.ref001" ref-type="bibr">1</xref>]. This includes IFN-&#x003b3;, an important inducer of IDO [<xref rid="pone.0227365.ref005" ref-type="bibr">5</xref>]. An <italic>in vitro</italic> study on monocytes exposed to IFN-&#x003b3; identified that Kyn, KTR, HK, and QA were the most responsive to IFN-&#x003b3; stimulation [<xref rid="pone.0227365.ref029" ref-type="bibr">29</xref>]. Furthermore, KTR is a marker of a cellular immune response, mainly reflecting monocyte activation [<xref rid="pone.0227365.ref005" ref-type="bibr">5</xref>]. The changes in circulating levels of mKP in heart failure observed in our data may thus reflect underlying monocyte activation, but might also related to reduced exercise in heart failure which can decrease clearance of mKP [<xref rid="pone.0227365.ref030" ref-type="bibr">30</xref>]. The changes in plasma KTR might also reflect increased TDO-activation and not only IDO-activation. Since this study does not include gene expression of TDO and IDO, dietary intake of Trp and hormone status, we cannot conclude that KTR represent only increased IDO-activation.</p><p>We observed associations between KTR, QA, and a trend for Kyn, and higher mortality in patients with heart failure. The control groups displayed attenuated, non-significant, effect sizes, perhaps indicating a vulnerability in patients with heart failure. Conceivably, myocardial fibrosis, a key driver of disease progression in heart failure, could be related to monocyte production of mKP. Such a hypothesis could be assessed in experimental studies [<xref rid="pone.0227365.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pone.0227365.ref033" ref-type="bibr">33</xref>]. Our findings could be related to underlying chronic inflammation induced by IFN-&#x003b3;. However, IFN-&#x003b3; has not emerged as a key prognostic predictor in heart failure, and studies show diverging results [<xref rid="pone.0227365.ref007" ref-type="bibr">7</xref>]. One possible explanation for this discrepancy might be that baseline measurements of Trp and Kyn are better long-term markers of inflammation than cytokines, as they are considered more stable in individuals over time [<xref rid="pone.0227365.ref028" ref-type="bibr">28</xref>, <xref rid="pone.0227365.ref034" ref-type="bibr">34</xref>]. As IDO activation, and the concentrations of Kyn, and Trp are immune-regulatory, the relationship with inflammation might be complex [<xref rid="pone.0227365.ref035" ref-type="bibr">35</xref>].</p><p>The HK/XA ratio was most significantly associated with mortality. This reflects the significant associations between HK and increased mortality and XA and lower mortality, where XA is the immediate metabolic product of HK. The associations between high HK and HK/XA ratio and mortality were also observed in patients with CAD, but with lower effect sizes. Low XA was associated with higher mortality in all groups. A similar relationship between the HK/XA ratio and mortality has been described in renal transplant recipients [<xref rid="pone.0227365.ref036" ref-type="bibr">36</xref>], showing that the association is not limited to patients with heart failure. In experimental studies, HK accelerates apoptosis and endothelial dysfunction in mice [<xref rid="pone.0227365.ref037" ref-type="bibr">37</xref>], and apoptosis in human cells [<xref rid="pone.0227365.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0227365.ref039" ref-type="bibr">39</xref>]. Of the mKP, XA is likely the most potent antioxidant [<xref rid="pone.0227365.ref040" ref-type="bibr">40</xref>]. The HK/XA ratio may reflect an imbalance between apoptotic stimuli and antioxidant capacity. This ratio has been established as a functional marker of vitamin B6 status, and an elevated HK/XA ratio may reflect reduced activity of the PLP-dependent enzyme KAT [<xref rid="pone.0227365.ref041" ref-type="bibr">41</xref>]. However, the results in this study were not confounded by PLP [<xref rid="pone.0227365.ref041" ref-type="bibr">41</xref>] levels, and PLP levels were not associated with mortality. KAT enzymes generating HK from XA also depend on &#x003b1;-keto acids, such as &#x003b1;-ketoglutarate [<xref rid="pone.0227365.ref042" ref-type="bibr">42</xref>], which we did not measure, but are unlikely to be rate limiting. The biological significance of this ratio in heart failure warrants future investigation.</p><p>The potential for anti-inflammatory therapy in cardiovascular disease has been highlighted with the successful trial targeting the interleukin-1&#x003b2; pathway in patients with established CAD [<xref rid="pone.0227365.ref043" ref-type="bibr">43</xref>]. Experimental studies, starting with animal models, are needed to understand if manipulation of the KP can be of benefit to patients with heart failure. Limitations to this study, that should be taken into account in future studies, include lack of repeated measures of mKP, as well as hormone-, and dietary status. Immune profiling, including measurements of cytokines and chemokines that can influence the KP, would also be beneficial. This study is an observational study and we can thus only conclude with associations between HF and mKP and not causal mechanisms. However, our study identifying mKP as prognostic markers, may indicate a future therapeutic potential.</p></sec><sec sec-type="conclusions" id="sec019"><title>Conclusion</title><p>In summary, we found that plasma levels of Kyn, HK, QA, and the ratios KTR and HK/XA are higher in heart failure compared to controls with or without CAD. Elevated plasma levels of HK and HK/XA were associated with increased mortality in both patients with heart failure and CAD, with larger effect size in patients with heart failure. QA and KTR were associated with increased mortality only in patients with heart failure. Low plasma levels of XA were associated with increased mortality in all groups. Our results indicate that future intervention on mKP may be of clinical interest.</p></sec><sec sec-type="supplementary-material" id="sec020"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0227365.s001"><label>S1 Table</label><caption><title>Levels of tryptophan and kynurenines in cases and controls.</title><p>Abbreviations: Trp, tryptophan; Kyn, kynurenine; HK, 3-hydroxykynurenine; KA, kynurenic acid; XA, xanthurenic acid; AA, anthranilic acid; HAA, 3-hydroxyanthranilic acid; QA, quinolinic acid; KTR, kynurenine-tryptophan ratio; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio. <sup>a</sup> Levels in median and (interquartile ranges). <sup>b</sup> Heart failure versus controls without coronary artery disease (NCAD-C, Mann-Whitney U test). <sup>c</sup> Heart failure versus controls with coronary artery disease (CAD-C, Mann-Whitney U test). * p-value &#x0003c; 0.05, ** p-value &#x0003c; 0.001.</p><p>(DOCX)</p></caption><media xlink:href="pone.0227365.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0227365.s002"><label>S1 Fig</label><caption><title>Receiver operating characteristic (ROC) curves, HF versus NCAD-C.</title><p>ROC curves from unadjusted and adjusted multivariate logistic regression HF versus NCAD-C as outcome. Mod-1: regression with only the confounders diabetes, glomerular filtration rate, pyridoxal 5&#x02019;phosphate and C-reactive protein included. Mod-2: mKP and ratios added to model. Abbreviations: AUC, area under curve; mKP, metabolites of the kynurenine pathway; Trp, tryptophan; Kyn, kynurenine; KTR, kynurenine-tryptophan ratio; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio.</p><p>(TIF)</p></caption><media xlink:href="pone.0227365.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0227365.s003"><label>S2 Fig</label><caption><title>Receiver operating characteristic (ROC) curves, HF versus CAD-C.</title><p>ROC curves from unadjusted and adjusted multivariate logistic regression HF versus CAD-C as outcome. Mod-1: regression with only the confounders diabetes, glomerular filtration rate, pyridoxal 5&#x02019;phosphate and C-reactive protein included. Mod-2: mKP and ratios added to model. Abbreviations: AUC, area under curve; mKP, metabolites of the kynurenine pathway; Trp, tryptophan; Kyn, kynurenine; HK, 3-hydroxykynurenine; KTR, kynurenine-tryptophan ratio; HK/XA, 3-hydroxykynurenine-xanthurenic acid ratio.</p><p>(TIF)</p></caption><media xlink:href="pone.0227365.s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We want to thank the recruiting study personnel and the staff performing the laboratory analyses at Bevital. We also thank the patients for their contribution.</p></ack><ref-list><title>References</title><ref id="pone.0227365.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Gullestad</surname><given-names>L</given-names></name>, <name><surname>Ueland</surname><given-names>T</given-names></name>, <name><surname>Vinge</surname><given-names>LE</given-names></name>, <name><surname>Finsen</surname><given-names>A</given-names></name>, <name><surname>Yndestad</surname><given-names>A</given-names></name>, <name><surname>Aukrust</surname><given-names>P</given-names></name>. <article-title>Inflammatory cytokines in heart failure: mediators and markers</article-title>. <source>Cardiology</source>. <year>2012</year>;<volume>122</volume>(<issue>1</issue>):<fpage>23</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1159/000338166</pub-id> .<pub-id pub-id-type="pmid">22699305</pub-id></mixed-citation></ref><ref id="pone.0227365.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Sawyer</surname><given-names>DB</given-names></name>. <article-title>Oxidative stress in heart failure: what are we missing?</article-title>
<source>Am J Med Sci</source>. <year>2011</year>;<volume>342</volume>(<issue>2</issue>):<fpage>120</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1097/MAJ.0b013e3182249fcd</pub-id> .<pub-id pub-id-type="pmid">21747279</pub-id></mixed-citation></ref><ref id="pone.0227365.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Bauersachs</surname><given-names>J</given-names></name>, <name><surname>Langer</surname><given-names>HF</given-names></name>. <article-title>Immune mechanisms in heart failure</article-title>. <source>Eur J Heart Fail</source>. <year>2017</year>;<volume>19</volume>(<issue>11</issue>):<fpage>1379</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1002/ejhf.942</pub-id> .<pub-id pub-id-type="pmid">28891154</pub-id></mixed-citation></ref><ref id="pone.0227365.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Sager</surname><given-names>HB</given-names></name>, <name><surname>Hulsmans</surname><given-names>M</given-names></name>, <name><surname>Lavine</surname><given-names>KJ</given-names></name>, <name><surname>Moreira</surname><given-names>MB</given-names></name>, <name><surname>Heidt</surname><given-names>T</given-names></name>, <name><surname>Courties</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure</article-title>. <source>Circ Res</source>. <year>2016</year>;<volume>119</volume>(<issue>7</issue>):<fpage>853</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309001</pub-id> .<pub-id pub-id-type="pmid">27444755</pub-id></mixed-citation></ref><ref id="pone.0227365.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Ueland</surname><given-names>PM</given-names></name>, <name><surname>McCann</surname><given-names>A</given-names></name>, <name><surname>Midttun</surname><given-names>O</given-names></name>, <name><surname>Ulvik</surname><given-names>A</given-names></name>. <article-title>Inflammation, vitamin B6 and related pathways</article-title>. <source>Mol Aspects Med</source>. <year>2017</year>;<volume>53</volume>:<fpage>10</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2016.08.001</pub-id> .<pub-id pub-id-type="pmid">27593095</pub-id></mixed-citation></ref><ref id="pone.0227365.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Badawy</surname><given-names>AAB</given-names></name>. <article-title>Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects</article-title>. <source>International journal of tryptophan research: IJTR</source>. <year>2017</year>;<volume>10</volume>:1178646917691938. <pub-id pub-id-type="doi">10.1177/1178646917691938</pub-id>
<pub-id pub-id-type="pmid">28469468</pub-id></mixed-citation></ref><ref id="pone.0227365.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Levick</surname><given-names>SP</given-names></name>, <name><surname>Goldspink</surname><given-names>PH</given-names></name>. <article-title>Could interferon-gamma be a therapeutic target for treating heart failure?</article-title>
<source>Heart Fail Rev</source>. <year>2014</year>;<volume>19</volume>(<issue>2</issue>):<fpage>227</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1007/s10741-013-9393-8</pub-id> .<pub-id pub-id-type="pmid">23589353</pub-id></mixed-citation></ref><ref id="pone.0227365.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Zuo</surname><given-names>H</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <name><surname>Ulvik</surname><given-names>A</given-names></name>, <name><surname>Eussen</surname><given-names>SJ</given-names></name>, <name><surname>Vollset</surname><given-names>SE</given-names></name>, <name><surname>Nygard</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Plasma Biomarkers of Inflammation, the Kynurenine Pathway, and Risks of All-Cause, Cancer, and Cardiovascular Disease Mortality: The Hordaland Health Study</article-title>. <source>American journal of epidemiology</source>. <year>2016</year>;<volume>183</volume>(<issue>4</issue>):<fpage>249</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwv242</pub-id> .<pub-id pub-id-type="pmid">26823439</pub-id></mixed-citation></ref><ref id="pone.0227365.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Pedersen</surname><given-names>ER</given-names></name>, <name><surname>Tuseth</surname><given-names>N</given-names></name>, <name><surname>Eussen</surname><given-names>SJ</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <name><surname>Strand</surname><given-names>E</given-names></name>, <name><surname>Svingen</surname><given-names>GF</given-names></name>, <etal>et al</etal>
<article-title>Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2015</year>;<volume>35</volume>(<issue>2</issue>):<fpage>455</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.114.304674</pub-id> .<pub-id pub-id-type="pmid">25524770</pub-id></mixed-citation></ref><ref id="pone.0227365.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Konishi</surname><given-names>M</given-names></name>, <name><surname>Ebner</surname><given-names>N</given-names></name>, <name><surname>Springer</surname><given-names>J</given-names></name>, <name><surname>Schefold</surname><given-names>JC</given-names></name>, <name><surname>Doehner</surname><given-names>W</given-names></name>, <name><surname>Dschietzig</surname><given-names>TB</given-names></name>, <etal>et al</etal>
<article-title>Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure- Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)</article-title>. <source>Circ J</source>. <year>2016</year>;<volume>81</volume>(<issue>1</issue>):<fpage>52</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1253/circj.CJ-16-0791</pub-id> .<pub-id pub-id-type="pmid">27904018</pub-id></mixed-citation></ref><ref id="pone.0227365.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Seccareccia</surname><given-names>F</given-names></name>, <name><surname>Zuccaro</surname><given-names>P</given-names></name>, <name><surname>Pacifici</surname><given-names>R</given-names></name>, <name><surname>Meli</surname><given-names>P</given-names></name>, <name><surname>Pannozzo</surname><given-names>F</given-names></name>, <name><surname>Freeman</surname><given-names>KM</given-names></name>, <etal>et al</etal>
<article-title>Serum cotinine as a marker of environmental tobacco smoke exposure in epidemiological studies: the experience of the MATISS project</article-title>. <source>European journal of epidemiology</source>. <year>2003</year>;<volume>18</volume>(<issue>6</issue>):<fpage>487</fpage>&#x02013;<lpage>92</lpage>. Epub 2003/08/12. <pub-id pub-id-type="doi">10.1023/a:1024672522802</pub-id> .<pub-id pub-id-type="pmid">12908713</pub-id></mixed-citation></ref><ref id="pone.0227365.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Pedersen</surname><given-names>AG</given-names></name>, <name><surname>Ellingsen</surname><given-names>CL</given-names></name>. <article-title>Data quality in the Causes of Death Registry</article-title>. <source>Tidsskr Nor Laegeforen</source>. <year>2015</year>;<volume>135</volume>(<issue>8</issue>):<fpage>768</fpage>&#x02013;<lpage>70</lpage>. .<pub-id pub-id-type="pmid">25947599</pub-id></mixed-citation></ref><ref id="pone.0227365.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Austin</surname><given-names>PC</given-names></name>. <article-title>A comparison of 12 algorithms for matching on the propensity score</article-title>. <source>Stat Med</source>. <year>2014</year>;<volume>33</volume>(<issue>6</issue>):<fpage>1057</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1002/sim.6004</pub-id> .<pub-id pub-id-type="pmid">24123228</pub-id></mixed-citation></ref><ref id="pone.0227365.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Midttun</surname><given-names>O</given-names></name>, <name><surname>Hustad</surname><given-names>S</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>. <article-title>Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography/tandem mass spectrometry</article-title>. <source>Rapid communications in mass spectrometry: RCM</source>. <year>2009</year>;<volume>23</volume>(<issue>9</issue>):<fpage>1371</fpage>&#x02013;<lpage>9</lpage>. Epub 2009/04/02. <pub-id pub-id-type="doi">10.1002/rcm.4013</pub-id> .<pub-id pub-id-type="pmid">19337982</pub-id></mixed-citation></ref><ref id="pone.0227365.ref015"><label>15</label><mixed-citation publication-type="book"><name><surname>Schafer</surname><given-names>JL</given-names></name>. <source>Analysis of incomplete multivariate data</source>: <publisher-name>Chapman and Hall/CRC</publisher-name>; <year>1997</year>.</mixed-citation></ref><ref id="pone.0227365.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>PH</given-names></name>. <article-title>Should we adjust for a confounder if empirical and theoretical criteria yield contradictory results? A simulation study</article-title>. <source>Sci Rep</source>. <year>2014</year>;<volume>4</volume>:<fpage>6085</fpage>
<pub-id pub-id-type="doi">10.1038/srep06085</pub-id> .<pub-id pub-id-type="pmid">25124526</pub-id></mixed-citation></ref><ref id="pone.0227365.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Ezekowitz</surname><given-names>J</given-names></name>, <name><surname>McAlister</surname><given-names>FA</given-names></name>, <name><surname>Humphries</surname><given-names>KH</given-names></name>, <name><surname>Norris</surname><given-names>CM</given-names></name>, <name><surname>Tonelli</surname><given-names>M</given-names></name>, <name><surname>Ghali</surname><given-names>WA</given-names></name>, <etal>et al</etal>
<article-title>The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. <year>2004</year>;<volume>44</volume>(<issue>8</issue>):<fpage>1587</fpage>&#x02013;<lpage>92</lpage>. Epub 2004/10/19. <pub-id pub-id-type="doi">10.1016/j.jacc.2004.06.072</pub-id> .<pub-id pub-id-type="pmid">15489090</pub-id></mixed-citation></ref><ref id="pone.0227365.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Aquilani</surname><given-names>R</given-names></name>, <name><surname>Opasich</surname><given-names>C</given-names></name>, <name><surname>Verri</surname><given-names>M</given-names></name>, <name><surname>Boschi</surname><given-names>F</given-names></name>, <name><surname>Febo</surname><given-names>O</given-names></name>, <name><surname>Pasini</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Is nutritional intake adequate in chronic heart failure patients?</article-title>
<source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>42</volume>(<issue>7</issue>):<fpage>1218</fpage>&#x02013;<lpage>23</lpage>. Epub 2003/10/03. <pub-id pub-id-type="doi">10.1016/s0735-1097(03)00946-x</pub-id> .<pub-id pub-id-type="pmid">14522484</pub-id></mixed-citation></ref><ref id="pone.0227365.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Pawlak</surname><given-names>K</given-names></name>, <name><surname>Domaniewski</surname><given-names>T</given-names></name>, <name><surname>Mysliwiec</surname><given-names>M</given-names></name>, <name><surname>Pawlak</surname><given-names>D</given-names></name>. <article-title>The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease</article-title>. <source>Atherosclerosis</source>. <year>2009</year>;<volume>204</volume>(<issue>1</issue>):<fpage>309</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2008.08.014</pub-id> .<pub-id pub-id-type="pmid">18823890</pub-id></mixed-citation></ref><ref id="pone.0227365.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Theofylaktopoulou</surname><given-names>D</given-names></name>, <name><surname>Midttun</surname><given-names>O</given-names></name>, <name><surname>Ulvik</surname><given-names>A</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <name><surname>Tell</surname><given-names>GS</given-names></name>, <name><surname>Vollset</surname><given-names>SE</given-names></name>, <etal>et al</etal>
<article-title>A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study</article-title>. <source>Clinical and experimental immunology</source>. <year>2013</year>;<volume>173</volume>(<issue>1</issue>):<fpage>121</fpage>&#x02013;<lpage>30</lpage>. Epub 2013/04/24. <pub-id pub-id-type="doi">10.1111/cei.12092</pub-id> .<pub-id pub-id-type="pmid">23607723</pub-id></mixed-citation></ref><ref id="pone.0227365.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Young</surname><given-names>SN</given-names></name>. <article-title>Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects</article-title>. <source>J Psychiatry Neurosci</source>. <year>2013</year>;<volume>38</volume>(<issue>5</issue>):<fpage>294</fpage>&#x02013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1503/jpn.120209</pub-id> .<pub-id pub-id-type="pmid">23428157</pub-id></mixed-citation></ref><ref id="pone.0227365.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Stone</surname><given-names>TW</given-names></name>, <name><surname>Darlington</surname><given-names>LG</given-names></name>. <article-title>Endogenous kynurenines as targets for drug discovery and development</article-title>. <source>Nat Rev Drug Discov</source>. <year>2002</year>;<volume>1</volume>(<issue>8</issue>):<fpage>609</fpage>&#x02013;<lpage>20</lpage>. Epub 2002/10/31. <pub-id pub-id-type="doi">10.1038/nrd870</pub-id> .<pub-id pub-id-type="pmid">12402501</pub-id></mixed-citation></ref><ref id="pone.0227365.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Parry</surname><given-names>HM</given-names></name>, <name><surname>Deshmukh</surname><given-names>H</given-names></name>, <name><surname>Levin</surname><given-names>D</given-names></name>, <name><surname>Van Zuydam</surname><given-names>N</given-names></name>, <name><surname>Elder</surname><given-names>DH</given-names></name>, <name><surname>Morris</surname><given-names>AD</given-names></name>, <etal>et al</etal>
<article-title>Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus</article-title>. <source>Circ Heart Fail</source>. <year>2015</year>;<volume>8</volume>(<issue>2</issue>):<fpage>236</fpage>&#x02013;<lpage>42</lpage>. Epub 2015/01/07. <pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.113.000920</pub-id> .<pub-id pub-id-type="pmid">25561089</pub-id></mixed-citation></ref><ref id="pone.0227365.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Theofylaktopoulou</surname><given-names>D</given-names></name>, <name><surname>Ulvik</surname><given-names>A</given-names></name>, <name><surname>Midttun</surname><given-names>O</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <name><surname>Vollset</surname><given-names>SE</given-names></name>, <name><surname>Nygard</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Vitamins B2 and B6 as determinants of kynurenines and related markers of interferon-gamma-mediated immune activation in the community-based Hordaland Health Study</article-title>. <source>Br J Nutr</source>. <year>2014</year>;<volume>112</volume>(<issue>7</issue>):<fpage>1065</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1017/S0007114514001858</pub-id> .<pub-id pub-id-type="pmid">25105221</pub-id></mixed-citation></ref><ref id="pone.0227365.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Anand</surname><given-names>IS</given-names></name>, <name><surname>Latini</surname><given-names>R</given-names></name>, <name><surname>Florea</surname><given-names>VG</given-names></name>, <name><surname>Kuskowski</surname><given-names>MA</given-names></name>, <name><surname>Rector</surname><given-names>T</given-names></name>, <name><surname>Masson</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>C-reactive protein in heart failure: prognostic value and the effect of valsartan</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>112</volume>(<issue>10</issue>):<fpage>1428</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.508465</pub-id> .<pub-id pub-id-type="pmid">16129801</pub-id></mixed-citation></ref><ref id="pone.0227365.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Liu</surname><given-names>D</given-names></name>, <name><surname>Song</surname><given-names>P</given-names></name>, <name><surname>Zou</surname><given-names>MH</given-names></name>. <article-title>Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation</article-title>. <source>Front Biosci (Landmark Ed)</source>. <year>2015</year>;<volume>20</volume>:<fpage>1116</fpage>&#x02013;<lpage>43</lpage>. Epub 2015/05/12. <pub-id pub-id-type="doi">10.2741/4363</pub-id> .<pub-id pub-id-type="pmid">25961549</pub-id></mixed-citation></ref><ref id="pone.0227365.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Zuo</surname><given-names>H</given-names></name>, <name><surname>Tell</surname><given-names>GS</given-names></name>, <name><surname>Vollset</surname><given-names>SE</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>, <name><surname>Nygard</surname><given-names>O</given-names></name>, <name><surname>Midttun</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Interferon-gamma-induced inflammatory markers and the risk of cancer: the Hordaland Health Study</article-title>. <source>Cancer</source>. <year>2014</year>;<volume>120</volume>(<issue>21</issue>):<fpage>3370</fpage>&#x02013;<lpage>7</lpage>. Epub 2014/06/21. <pub-id pub-id-type="doi">10.1002/cncr.28869</pub-id> .<pub-id pub-id-type="pmid">24948355</pub-id></mixed-citation></ref><ref id="pone.0227365.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Midttun</surname><given-names>O</given-names></name>, <name><surname>Townsend</surname><given-names>MK</given-names></name>, <name><surname>Nygard</surname><given-names>O</given-names></name>, <name><surname>Tworoger</surname><given-names>SS</given-names></name>, <name><surname>Brennan</surname><given-names>P</given-names></name>, <name><surname>Johansson</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Most blood biomarkers related to vitamin status, one-carbon metabolism, and the kynurenine pathway show adequate preanalytical stability and within-person reproducibility to allow assessment of exposure or nutritional status in healthy women and cardiovascular patients</article-title>. <source>J Nutr</source>. <year>2014</year>;<volume>144</volume>(<issue>5</issue>):<fpage>784</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.3945/jn.113.189738</pub-id> .<pub-id pub-id-type="pmid">24647388</pub-id></mixed-citation></ref><ref id="pone.0227365.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>SP</given-names></name>, <name><surname>Franco</surname><given-names>NF</given-names></name>, <name><surname>Varney</surname><given-names>B</given-names></name>, <name><surname>Sundaram</surname><given-names>G</given-names></name>, <name><surname>Brown</surname><given-names>DA</given-names></name>, <name><surname>de Bie</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>6</issue>):<fpage>e0131389</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0131389</pub-id> .<pub-id pub-id-type="pmid">26114426</pub-id></mixed-citation></ref><ref id="pone.0227365.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Cervenka</surname><given-names>I</given-names></name>, <name><surname>Agudelo</surname><given-names>LZ</given-names></name>, <name><surname>Ruas</surname><given-names>JL</given-names></name>. <article-title>Kynurenines: Tryptophan&#x02019;s metabolites in exercise, inflammation, and mental health</article-title>. <source>Science</source>. <year>2017</year>;<volume>357</volume>(<issue>6349</issue>). <pub-id pub-id-type="doi">10.1126/science.aaf9794</pub-id> .<pub-id pub-id-type="pmid">28751584</pub-id></mixed-citation></ref><ref id="pone.0227365.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Hulsmans</surname><given-names>M</given-names></name>, <name><surname>Sam</surname><given-names>F</given-names></name>, <name><surname>Nahrendorf</surname><given-names>M</given-names></name>. <article-title>Monocyte and macrophage contributions to cardiac remodeling</article-title>. <source>J Mol Cell Cardiol</source>. <year>2016</year>;<volume>93</volume>:<fpage>149</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.11.015</pub-id> .<pub-id pub-id-type="pmid">26593722</pub-id></mixed-citation></ref><ref id="pone.0227365.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Gulati</surname><given-names>A</given-names></name>, <name><surname>Jabbour</surname><given-names>A</given-names></name>, <name><surname>Ismail</surname><given-names>TF</given-names></name>, <name><surname>Guha</surname><given-names>K</given-names></name>, <name><surname>Khwaja</surname><given-names>J</given-names></name>, <name><surname>Raza</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>309</volume>(<issue>9</issue>):<fpage>896</fpage>&#x02013;<lpage>908</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.1363</pub-id> .<pub-id pub-id-type="pmid">23462786</pub-id></mixed-citation></ref><ref id="pone.0227365.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Ho</surname><given-names>JE</given-names></name>, <name><surname>Liu</surname><given-names>C</given-names></name>, <name><surname>Lyass</surname><given-names>A</given-names></name>, <name><surname>Courchesne</surname><given-names>P</given-names></name>, <name><surname>Pencina</surname><given-names>MJ</given-names></name>, <name><surname>Vasan</surname><given-names>RS</given-names></name>, <etal>et al</etal>
<article-title>Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community</article-title>. <source>J Am Coll Cardiol</source>. <year>2012</year>;<volume>60</volume>(<issue>14</issue>):<fpage>1249</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2012.04.053</pub-id> .<pub-id pub-id-type="pmid">22939561</pub-id></mixed-citation></ref><ref id="pone.0227365.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Aziz</surname><given-names>N</given-names></name>, <name><surname>Detels</surname><given-names>R</given-names></name>, <name><surname>Quint</surname><given-names>JJ</given-names></name>, <name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Gjertson</surname><given-names>D</given-names></name>, <name><surname>Butch</surname><given-names>AW</given-names></name>. <article-title>Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions</article-title>. <source>Cytokine</source>. <year>2016</year>;<volume>84</volume>:<fpage>17</fpage>&#x02013;<lpage>24</lpage>. Epub 2016/05/22. <pub-id pub-id-type="doi">10.1016/j.cyto.2016.05.010</pub-id> .<pub-id pub-id-type="pmid">27208752</pub-id></mixed-citation></ref><ref id="pone.0227365.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Mandi</surname><given-names>Y</given-names></name>, <name><surname>Vecsei</surname><given-names>L</given-names></name>. <article-title>The kynurenine system and immunoregulation</article-title>. <source>J Neural Transm (Vienna)</source>. <year>2012</year>;<volume>119</volume>(<issue>2</issue>):<fpage>197</fpage>&#x02013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-011-0681-y</pub-id> .<pub-id pub-id-type="pmid">21744051</pub-id></mixed-citation></ref><ref id="pone.0227365.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Minovic</surname><given-names>I</given-names></name>, <name><surname>van der Veen</surname><given-names>A</given-names></name>, <name><surname>van Faassen</surname><given-names>M</given-names></name>, <name><surname>Riphagen</surname><given-names>IJ</given-names></name>, <name><surname>van den Berg</surname><given-names>E</given-names></name>, <name><surname>van der Ley</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Functional vitamin B-6 status and long-term mortality in renal transplant recipients</article-title>. <source>Am J Clin Nutr</source>. <year>2017</year>;<volume>106</volume>(<issue>6</issue>):<fpage>1366</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.3945/ajcn.117.164012</pub-id> .<pub-id pub-id-type="pmid">28978540</pub-id></mixed-citation></ref><ref id="pone.0227365.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Ding</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Song</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Activation of NAD(P)H oxidase by tryptophan-derived 3-hydroxykynurenine accelerates endothelial apoptosis and dysfunction in vivo</article-title>. <source>Circ Res</source>. <year>2014</year>;<volume>114</volume>(<issue>3</issue>):<fpage>480</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302113</pub-id> .<pub-id pub-id-type="pmid">24281189</pub-id></mixed-citation></ref><ref id="pone.0227365.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Mailankot</surname><given-names>M</given-names></name>, <name><surname>Nagaraj</surname><given-names>RH</given-names></name>. <article-title>Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human lens epithelial cells: apoptosis through the formation of 3-hydroxykynurenine</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2010</year>;<volume>42</volume>(<issue>9</issue>):<fpage>1446</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2010.04.014</pub-id> .<pub-id pub-id-type="pmid">20435158</pub-id></mixed-citation></ref><ref id="pone.0227365.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Wei</surname><given-names>H</given-names></name>, <name><surname>Leeds</surname><given-names>P</given-names></name>, <name><surname>Chen</surname><given-names>RW</given-names></name>, <name><surname>Wei</surname><given-names>W</given-names></name>, <name><surname>Leng</surname><given-names>Y</given-names></name>, <name><surname>Bredesen</surname><given-names>DE</given-names></name>, <etal>et al</etal>
<article-title>Neuronal apoptosis induced by pharmacological concentrations of 3-hydroxykynurenine: characterization and protection by dantrolene and Bcl-2 overexpression</article-title>. <source>J Neurochem</source>. <year>2000</year>;<volume>75</volume>(<issue>1</issue>):<fpage>81</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.0750081.x</pub-id> .<pub-id pub-id-type="pmid">10854250</pub-id></mixed-citation></ref><ref id="pone.0227365.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Reyes Ocampo</surname><given-names>J</given-names></name>, <name><surname>Lugo Huitron</surname><given-names>R</given-names></name>, <name><surname>Gonzalez-Esquivel</surname><given-names>D</given-names></name>, <name><surname>Ugalde-Muniz</surname><given-names>P</given-names></name>, <name><surname>Jimenez-Anguiano</surname><given-names>A</given-names></name>, <name><surname>Pineda</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases</article-title>. <source>Oxid Med Cell Longev</source>. <year>2014</year>;<volume>2014</volume>:646909. <pub-id pub-id-type="doi">10.1155/2014/646909</pub-id> .<pub-id pub-id-type="pmid">24693337</pub-id></mixed-citation></ref><ref id="pone.0227365.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Ulvik</surname><given-names>A</given-names></name>, <name><surname>Theofylaktopoulou</surname><given-names>D</given-names></name>, <name><surname>Midttun</surname><given-names>O</given-names></name>, <name><surname>Nygard</surname><given-names>O</given-names></name>, <name><surname>Eussen</surname><given-names>SJ</given-names></name>, <name><surname>Ueland</surname><given-names>PM</given-names></name>. <article-title>Substrate product ratios of enzymes in the kynurenine pathway measured in plasma as indicators of functional vitamin B-6 status</article-title>. <source>Am J Clin Nutr</source>. <year>2013</year>;<volume>98</volume>(<issue>4</issue>):<fpage>934</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.3945/ajcn.113.064998</pub-id> .<pub-id pub-id-type="pmid">24004893</pub-id></mixed-citation></ref><ref id="pone.0227365.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>Q</given-names></name>, <name><surname>Cai</surname><given-names>T</given-names></name>, <name><surname>Tagle</surname><given-names>DA</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>. <article-title>Structure, expression, and function of kynurenine aminotransferases in human and rodent brains</article-title>. <source>Cell Mol Life Sci</source>. <year>2010</year>;<volume>67</volume>(<issue>3</issue>):<fpage>353</fpage>&#x02013;<lpage>68</lpage>. Epub 2009/10/15. <pub-id pub-id-type="doi">10.1007/s00018-009-0166-4</pub-id> .<pub-id pub-id-type="pmid">19826765</pub-id></mixed-citation></ref><ref id="pone.0227365.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Ridker</surname><given-names>PM</given-names></name>, <name><surname>Everett</surname><given-names>BM</given-names></name>, <name><surname>Thuren</surname><given-names>T</given-names></name>, <name><surname>MacFadyen</surname><given-names>JG</given-names></name>, <name><surname>Chang</surname><given-names>WH</given-names></name>, <name><surname>Ballantyne</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>12</issue>):<fpage>1119</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id> .<pub-id pub-id-type="pmid">28845751</pub-id></mixed-citation></ref></ref-list></back></article>